Regeneron Faces Uphill Battle in Willful Patent Infringement Case Over COVID-19 Innovations

In a recent decision, a New York federal judge ruled that Regeneron Pharmaceuticals Inc. cannot dismiss a willful infringement claim in an ongoing patent lawsuit brought by Allele Biotech. The case revolves around the development of COVID-19 vaccines and treatments, with Allele Biotech alleging that Regeneron willfully infringed on its patent rights. The court emphasized that it is Regeneron’s responsibility to prove that Allele Biotech failed to demonstrate Regeneron’s presuit knowledge of the patent in question. The ruling maintains the focus on Regeneron’s alleged awareness of the patent before the lawsuit, a critical component of Allele’s claims. For further details, visit the article on Law360.